Summary of the technology
Repurposed antidepressant agents for treating levodopa-induced dyskinesia (LID) in Parkinson's disease dramatically reduced LID and maintained these effects for several weeks without altering L-DOPA’s positive anti-parkinsonian effects.
Description of the technology
Dopamine replacement therapy with L-DOPA remains the gold-standard treatment for the crippling movement disruptions affecting >10 million Parkinson’s Disease patients worldwide. However, L-DOPA therapies, especially after prolonged use, are associated with painful and disabling abnormal involuntary movements termed L-DOPA induced dyskinesia (LID), which affect nearly 90% of patients within 10 years of commencing treatment. An estimated >2 million Parkinson’s disease patients worldwide will exhibit extremely disruptive LID this year alone.
Given that L-DOPA remains the most effective Parkinson’s treatment option, substantial research has focused on addressing this problem, yet without much success in the translation to the clinical setting. Recently, amantadine has become the first drug to be repurposed and approved for LID mitigation, but has encountered roadblocks in the clinic, including limited efficacy and major side effects.
Binghamton University researchers have developed a new method for treating LID in Parkinson’s disease, demonstrating for the first time the anti-dyskinetic potential of dual partial 5-HT1A agonist/SSRI agents, including the FDA-approved antidepressants vilazodone (Viibryd) and vortioxetine (Trintellix). The dual-activity antidepressants dramatically reduced LID and maintained these effects for several weeks without altering L-DOPA’s positive anti-parkinsonian effects.
- More effective than currently approved therapy.
- Potent and stable response.
- Reduced side effect profile.
- FDA-approved compounds positioned for rapid repurposing.
- Effective in prevention and treatment of LID in Parkinson’s patients.
Technology Transfer Office